Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain)

Background In Catalonia, infants under 6 months old were eligible to receive nirsevimab, a novel monoclonal antibody against respiratory syncytial virus (RSV). We aimed to analyse nirsevimab's effectiveness across primary and hospital care outcomes.Methods Retrospective cohort study from 1 Octo...

ver descrição completa

Detalhes bibliográficos
Autores: Coma, E, Martinez-Marcos, M, Hermosilla, E, Mendioroz, J, Reñé, A, Fina, F, Perramon-Malavez, A, Prats, C, Cereza, G, Ciruela, P, Pineda, V, Antón, A, Ricós-Furió, G, Soriano-Arandes, A, Cabezas, C
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Recursos:Institut d'Investigació i Innovació Parc Taulí (I3PT)
Repositorio:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
OAI Identifier:oai:i3pt.fundanetsuite.com:p4932
Acesso em linha:https://i3pt.portalinvestigacion.com/publicaciones/4932
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85196784733&doi=10.1136%2farchdischild-2024-327153&partnerID=40&md5=d433352883007ea1f4a9c47ad8381d70
Access Level:acceso abierto
Palavra-chave:Immunisation
Child Health
Infectious Disease Medicine
Respiratory Medicine
id ES_d9ec4c3aa88cae45dab434600d4d44f3
oai_identifier_str oai:i3pt.fundanetsuite.com:p4932
network_acronym_str ES
network_name_str España
repository_id_str
spelling Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain)Coma, EMartinez-Marcos, MHermosilla, EMendioroz, JReñé, AFina, FPerramon-Malavez, APrats, CCereza, GCiruela, PPineda, VAntón, ARicós-Furió, GSoriano-Arandes, ACabezas, CImmunisationChild HealthInfectious Disease MedicineRespiratory MedicineBackground In Catalonia, infants under 6 months old were eligible to receive nirsevimab, a novel monoclonal antibody against respiratory syncytial virus (RSV). We aimed to analyse nirsevimab's effectiveness across primary and hospital care outcomes.Methods Retrospective cohort study from 1 October 2023 to 31 January 2024, including all infants born between April and September 2023. We established two cohorts based on nirsevimab administration (immunised and non-immunised). We followed individuals until the earliest moment of an outcome-RSV infection, primary care attended bronchiolitis and pneumonia, hospital emergency visits due to bronchiolitis, hospital admission or intensive care unit (ICU) admission due to RSV bronchiolitis-death or the end of the study. We used the Kaplan-Meier estimator and fitted Cox regression models using a calendar time scale to estimate HRs and their 95% CIs.Results Among 26 525 infants, a dose of nirsevimab led to an adjusted HR for hospital admission due to RSV bronchiolitis of 0.124 (95% CI: 0.086 to 0.179) and an adjusted HR for ICU admission of 0.099 (95% CI: 0.041 to 0.237). Additionally, the adjusted HRs observed for emergency visits were 0.446 (95% CI: 0.385 to 0.516) and 0.393 (95% CI: 0.203 to 0.758) for viral pneumonia, 0.519 (95% CI: 0.467 to 0.576) for bronchiolitis attended in primary care and 0.311 (95% CI: 0.200 to 0.483) for RSV infection.Conclusion We demonstrated nirsevimab's effectiveness with reductions of 87.6% and 90.1% in hospital and ICU admissions, respectively. These findings offer crucial guidance for public health authorities in implementing RSV immunisation campaigns.BMJ PUBLISHING GROUP2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://i3pt.portalinvestigacion.com/publicaciones/4932https://www.scopus.com/inward/record.uri?eid=2-s2.0-85196784733&doi=10.1136%2farchdischild-2024-327153&partnerID=40&md5=d433352883007ea1f4a9c47ad8381d70ARCHIVES OF DISEASE IN CHILDHOODISSN: 00039888ISSNe: 14682044reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulíinstname:Institut d'Investigació i Innovació Parc Taulí (I3PT)Inglésinfo:eu-repo/semantics/openAccessoai:i3pt.fundanetsuite.com:p49322026-06-21T15:30:37Z
dc.title.none.fl_str_mv Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain)
title Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain)
spellingShingle Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain)
Coma, E
Immunisation
Child Health
Infectious Disease Medicine
Respiratory Medicine
title_short Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain)
title_full Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain)
title_fullStr Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain)
title_full_unstemmed Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain)
title_sort Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain)
dc.creator.none.fl_str_mv Coma, E
Martinez-Marcos, M
Hermosilla, E
Mendioroz, J
Reñé, A
Fina, F
Perramon-Malavez, A
Prats, C
Cereza, G
Ciruela, P
Pineda, V
Antón, A
Ricós-Furió, G
Soriano-Arandes, A
Cabezas, C
author Coma, E
author_facet Coma, E
Martinez-Marcos, M
Hermosilla, E
Mendioroz, J
Reñé, A
Fina, F
Perramon-Malavez, A
Prats, C
Cereza, G
Ciruela, P
Pineda, V
Antón, A
Ricós-Furió, G
Soriano-Arandes, A
Cabezas, C
author_role author
author2 Martinez-Marcos, M
Hermosilla, E
Mendioroz, J
Reñé, A
Fina, F
Perramon-Malavez, A
Prats, C
Cereza, G
Ciruela, P
Pineda, V
Antón, A
Ricós-Furió, G
Soriano-Arandes, A
Cabezas, C
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Immunisation
Child Health
Infectious Disease Medicine
Respiratory Medicine
topic Immunisation
Child Health
Infectious Disease Medicine
Respiratory Medicine
description Background In Catalonia, infants under 6 months old were eligible to receive nirsevimab, a novel monoclonal antibody against respiratory syncytial virus (RSV). We aimed to analyse nirsevimab's effectiveness across primary and hospital care outcomes.Methods Retrospective cohort study from 1 October 2023 to 31 January 2024, including all infants born between April and September 2023. We established two cohorts based on nirsevimab administration (immunised and non-immunised). We followed individuals until the earliest moment of an outcome-RSV infection, primary care attended bronchiolitis and pneumonia, hospital emergency visits due to bronchiolitis, hospital admission or intensive care unit (ICU) admission due to RSV bronchiolitis-death or the end of the study. We used the Kaplan-Meier estimator and fitted Cox regression models using a calendar time scale to estimate HRs and their 95% CIs.Results Among 26 525 infants, a dose of nirsevimab led to an adjusted HR for hospital admission due to RSV bronchiolitis of 0.124 (95% CI: 0.086 to 0.179) and an adjusted HR for ICU admission of 0.099 (95% CI: 0.041 to 0.237). Additionally, the adjusted HRs observed for emergency visits were 0.446 (95% CI: 0.385 to 0.516) and 0.393 (95% CI: 0.203 to 0.758) for viral pneumonia, 0.519 (95% CI: 0.467 to 0.576) for bronchiolitis attended in primary care and 0.311 (95% CI: 0.200 to 0.483) for RSV infection.Conclusion We demonstrated nirsevimab's effectiveness with reductions of 87.6% and 90.1% in hospital and ICU admissions, respectively. These findings offer crucial guidance for public health authorities in implementing RSV immunisation campaigns.
publishDate 2024
dc.date.none.fl_str_mv 2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://i3pt.portalinvestigacion.com/publicaciones/4932
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85196784733&doi=10.1136%2farchdischild-2024-327153&partnerID=40&md5=d433352883007ea1f4a9c47ad8381d70
url https://i3pt.portalinvestigacion.com/publicaciones/4932
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85196784733&doi=10.1136%2farchdischild-2024-327153&partnerID=40&md5=d433352883007ea1f4a9c47ad8381d70
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv BMJ PUBLISHING GROUP
publisher.none.fl_str_mv BMJ PUBLISHING GROUP
dc.source.none.fl_str_mv ARCHIVES OF DISEASE IN CHILDHOOD
ISSN: 00039888
ISSNe: 14682044
reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
instname:Institut d'Investigació i Innovació Parc Taulí (I3PT)
instname_str Institut d'Investigació i Innovació Parc Taulí (I3PT)
reponame_str r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
collection r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869421480524120064
score 15,812429

Registos relacionados